financetom
Business
financetom
/
Business
/
Blueprint Medicines' Q1 Earnings Decline, Revenue Increases
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Blueprint Medicines' Q1 Earnings Decline, Revenue Increases
May 25, 2025 11:21 PM

09:40 AM EDT, 05/01/2025 (MT Newswires) -- Blueprint Medicines ( BPMC ) reported Q1 earnings Thursday of $0.01 per diluted share, down from $1.40 a year earlier.

Analysts polled by FactSet expected a loss of $0.49 per share.

Revenue for the quarter ended March 31 was $149.4 million, compared with $96.1 million a year earlier.

Analysts surveyed by FactSet expected $155.5 million.

Price: 91.33, Change: +1.83, Percent Change: +2.04

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved